“I called my son after hearing the rumors and he told me that the rumors are true. “The speaker is Jacob Partey, Thomas’s father. He does it in Entsie at Tru FM and confirms not only Arsenal’s interest in signing his son but also contacts. “He told me that they are having talks between him and Arsenal. It all depends on the offer that Atlético demands“He added. Some statements that, However, shortly afterwards the soccer player’s representation agency, JJ Sports, came out to deny, with the approval of the player. “It is totally false that we are negotiating with Arsenal”, They replied forcefully. Everything remains the same with Thomas, which continues without signing the renewal offer with a millionaire salary and clause proposed by the rojiblanco club in October. His release now costs 50 million, a trifle for a superclass. Far from the three-digit armor, one hundred million, with which Atlético intends to arm him. Hence, the statements of the player’s father concern both the club and the fans with phrases like this: “What they are discussing now is how Atlético will release him” Thomas’ death for Cholo would be a near-fatal injury. Basic footballer in his scheme, irreplaceable, last season when he shared midfield with a footballer from whom as many hopes as Rodrigo Hernández hung, Simeone was clear with the directive when from the City of Guardiola the siren songs began that ended by take it to the Premier. “The undisputed is Thomas“This season even more. But, according to the statements of his father, his continuity is more in the air than ever. Jacob Partey, even talked about how he sees him with the Arteta team shirt.”If Arsenal does well, they have a large following in Ghana. I will be happy if you decide to move to Arsenal“The Champions, keyAtlético needs to qualify for the Champions League, a competition that this season has already reported more than 70 million euros in revenue, but wants to be in the position of having to sell one of its stars to survive. Stars that the Premier wants. Stars called Saúl (especially; United loves him), surnamed Partey (Arsenal). The statements of the father of the latter alert the Metropolitan Wanda that he has one of his priorities in the coming weeks: that Thomas sign that renewal He has been waiting on his table since October, clinging more to the denial of the player’s representation agency than to the words of his father. Because the rumors from London do not stop increasing. Arsenal, as revealed by Daily Mail A few months ago, he would have already made a bid of 50 million for Thomas while Simeone prays that nothing happens.
Jun 12 2018Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy. The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine tumor cells.Dr. Jonathan Strosberg, head of Neuroendocrine Tumor Program at Moffitt “Treatment options have been limited for patients with neuroendocrine tumors and toxicities of treatment can often outweigh the benefit. Our studies have shown Lutathera is an effective option to treat tumor progression and also provide patients with a better quality of life,” said Jonathan R. Strosberg, M.D., head of the Neuroendocrine Tumor Program at Moffitt Cancer Center.Related StoriesStudy reports role of cancer gene in tumor microenvironmentScientists use advanced imaging to track brain tumor ‘turncoats’Bordeaux University Hospital uses 3D printing to improve kidney tumor removal surgeryThe Journal of Clinical Oncology published new data from the NETTER-1 clinical trial highlighting the impact of Lutathera on patients’ quality of life. Strosberg notes the importance of this issue, given the relatively long durations of treatments and overall survival compared to other malignancies. The results showed that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients compared to those treated with octreotide LAR alone.Patients in the study were given questionnaires every three months until tumor progression. Quality of life was measured by global health status, physical functioning, role functioning, fatigue, pain, diarrhea, disease-related worries and body image. The time of deterioration was defined as the period of time from the patient’s first questionnaire response until their quality of life score declined ten or more points.Patients treated with Lutathera reported improvement in many of the typical side effects, such as fatigue, pain and diarrhea. Differences in the median time to deterioration were 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning. Source:https://www.moffitt.org/newsroom/press-release-archive/2018/newly-approved-therapy-provides-improved-quality-of-life-for-patients-with-advanced-metastatic-midgut-neuroendocrine-tumors/